# PeptideScanner evidence objects: Pasireotide

Every published version of the records placed with Pasireotide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/pasireotide.json. Selected public evidence only; not medical advice.

- Objects: 63
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00171730-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT00171730

> PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct00171730-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-09-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00171730-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00171730-pasireotide-v1
- Content SHA-256: `8fc94c57bb95149f94983fa51272e0b90897103e237a65277801ee2d1103837a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00171730 ([`ctg-observation-nct00171730-2021-09-05-8b84573fefb2`](#source-ctg-observation-nct00171730-2021-09-05-8b84573fefb2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00171730-2021-09-05-8b84573fefb2`](#source-ctg-observation-nct00171730-2021-09-05-8b84573fefb2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00171730-2021-09-05-8b84573fefb2`](#source-ctg-observation-nct00171730-2021-09-05-8b84573fefb2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00171730-2021-09-05-8b84573fefb2`](#source-ctg-observation-nct00171730-2021-09-05-8b84573fefb2))

### Sources

<a id="source-ctg-observation-nct00171730-2021-09-05-8b84573fefb2"></a>
- **ClinicalTrials.gov record NCT00171730 · retained source version 2021-09-05:8b84573fefb26c786e5db677f648dc3424dfca2de4dcf37b515751865ae93158** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00171730) (`ctg-observation-nct00171730-2021-09-05-8b84573fefb2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00171730." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00171730-pasireotide-v1 SHA-256: 8fc94c57bb95149f94983fa51272e0b90897103e237a65277801ee2d1103837a.

---

<a id="clinicaltrials-gov-nct00171951-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT00171951

> PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct00171951-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00171951-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00171951-pasireotide-v1
- Content SHA-256: `44744f90b183b39a9f7080811e95fa4047ebb4ed796edcb28e0f677c81e2d56f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00171951 ([`ctg-observation-nct00171951-2021-06-02-1bff69abb003`](#source-ctg-observation-nct00171951-2021-06-02-1bff69abb003))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00171951-2021-06-02-1bff69abb003`](#source-ctg-observation-nct00171951-2021-06-02-1bff69abb003))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00171951-2021-06-02-1bff69abb003`](#source-ctg-observation-nct00171951-2021-06-02-1bff69abb003))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00171951-2021-06-02-1bff69abb003`](#source-ctg-observation-nct00171951-2021-06-02-1bff69abb003))

### Sources

<a id="source-ctg-observation-nct00171951-2021-06-02-1bff69abb003"></a>
- **ClinicalTrials.gov record NCT00171951 · retained source version 2021-06-02:1bff69abb003bfa6c5480d813bed78bf8733085bc0708dd6e08a6d4363d02ffd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00171951) (`ctg-observation-nct00171951-2021-06-02-1bff69abb003`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00171951." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00171951-pasireotide-v1 SHA-256: 44744f90b183b39a9f7080811e95fa4047ebb4ed796edcb28e0f677c81e2d56f.

---

<a id="clinicaltrials-gov-nct00434148-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT00434148

> PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct00434148-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-03-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00434148-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00434148-pasireotide-v1
- Content SHA-256: `5043a4a81cb942cd8b0fb692a61c0a135c228a0881ad4022b609c47da3f311ba`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00434148 ([`ctg-observation-nct00434148-2016-03-08-7553b764cd55`](#source-ctg-observation-nct00434148-2016-03-08-7553b764cd55))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00434148-2016-03-08-7553b764cd55`](#source-ctg-observation-nct00434148-2016-03-08-7553b764cd55))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00434148-2016-03-08-7553b764cd55`](#source-ctg-observation-nct00434148-2016-03-08-7553b764cd55))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00434148-2016-03-08-7553b764cd55`](#source-ctg-observation-nct00434148-2016-03-08-7553b764cd55))

### Sources

<a id="source-ctg-observation-nct00434148-2016-03-08-7553b764cd55"></a>
- **ClinicalTrials.gov record NCT00434148 · retained source version 2016-03-08:7553b764cd55267eb5cc66291c2a405c70f31e5bae2148c124de36d5f40f6b40** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00434148) (`ctg-observation-nct00434148-2016-03-08-7553b764cd55`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00434148." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00434148-pasireotide-v1 SHA-256: 5043a4a81cb942cd8b0fb692a61c0a135c228a0881ad4022b609c47da3f311ba.

---

<a id="clinicaltrials-gov-nct00446082-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT00446082

> PeptideScanner retained ClinicalTrials.gov record NCT00446082 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct00446082-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00446082-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00446082-pasireotide-v1
- Content SHA-256: `ef619114deafe85c5f54490a0bba4250b4720307587f4ea4bfce143e1b5e0813`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00446082 ([`ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef`](#source-ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00446082 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef`](#source-ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00446082 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef`](#source-ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef`](#source-ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef))

### Sources

<a id="source-ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef"></a>
- **ClinicalTrials.gov record NCT00446082 · retained source version 2020-12-21:ae1e8899f0eff92d7a5655e0bfcc2852940b813ca5076a82bb2c3bf04e8a2740** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00446082) (`ctg-observation-nct00446082-2020-12-21-ae1e8899f0ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00446082." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00446082-pasireotide-v1 SHA-256: ef619114deafe85c5f54490a0bba4250b4720307587f4ea4bfce143e1b5e0813.

---

<a id="clinicaltrials-gov-nct00698464-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT00698464

> PeptideScanner retained ClinicalTrials.gov record NCT00698464 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct00698464-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00698464-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00698464-pasireotide-v1
- Content SHA-256: `5ce90f707ef0aae29ebca9ff704b0a13e1c9135f3267766632f6505367de2a4f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00698464 ([`ctg-observation-nct00698464-2020-12-21-ed3e224f81bb`](#source-ctg-observation-nct00698464-2020-12-21-ed3e224f81bb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00698464 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00698464-2020-12-21-ed3e224f81bb`](#source-ctg-observation-nct00698464-2020-12-21-ed3e224f81bb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00698464 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00698464-2020-12-21-ed3e224f81bb`](#source-ctg-observation-nct00698464-2020-12-21-ed3e224f81bb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00698464-2020-12-21-ed3e224f81bb`](#source-ctg-observation-nct00698464-2020-12-21-ed3e224f81bb))

### Sources

<a id="source-ctg-observation-nct00698464-2020-12-21-ed3e224f81bb"></a>
- **ClinicalTrials.gov record NCT00698464 · retained source version 2020-12-21:ed3e224f81bb997ccb30fb56e7730dc96d68799d83166d9c509acf71a112b09e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00698464) (`ctg-observation-nct00698464-2020-12-21-ed3e224f81bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00698464." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00698464-pasireotide-v1 SHA-256: 5ce90f707ef0aae29ebca9ff704b0a13e1c9135f3267766632f6505367de2a4f.

---

<a id="clinicaltrials-gov-nct00804336-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT00804336

> PeptideScanner retained ClinicalTrials.gov record NCT00804336 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-10-19, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct00804336-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-10-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00804336-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00804336-pasireotide-v1
- Content SHA-256: `b69d0c11986870b859ed8528be12a57f24108efcbd580a4587ae6e008b4c0ffe`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00804336 ([`ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0`](#source-ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00804336 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-10-19, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0`](#source-ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00804336 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-10-19, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0`](#source-ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0`](#source-ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0))

### Sources

<a id="source-ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0"></a>
- **ClinicalTrials.gov record NCT00804336 · retained source version 2016-10-19:32b4f4e3afe0c762102f6e6caf44c8b00f446fcb4df0c522b0e10df4141756fc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00804336) (`ctg-observation-nct00804336-2016-10-19-32b4f4e3afe0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00804336." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct00804336-pasireotide-v1 SHA-256: b69d0c11986870b859ed8528be12a57f24108efcbd580a4587ae6e008b4c0ffe.

---

<a id="clinicaltrials-gov-nct01128192-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01128192

> PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01128192-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-12-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01128192-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01128192-pasireotide-v1
- Content SHA-256: `7d141f2b595e31a363531cfc1e52976136d9450348c306eb36aefc120e5d60ca`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01128192 ([`ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc`](#source-ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc`](#source-ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc`](#source-ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc`](#source-ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc))

### Sources

<a id="source-ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc"></a>
- **ClinicalTrials.gov record NCT01128192 · retained source version 2014-12-25:ee14fc3cdebc24510d56f05e9787b3fe81314ddfc492ea38ab1616fc83145f1b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01128192) (`ctg-observation-nct01128192-2014-12-25-ee14fc3cdebc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01128192." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01128192-pasireotide-v1 SHA-256: 7d141f2b595e31a363531cfc1e52976136d9450348c306eb36aefc120e5d60ca.

---

<a id="clinicaltrials-gov-nct01137682-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01137682

> PeptideScanner retained ClinicalTrials.gov record NCT01137682 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-04-05, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01137682-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-04-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01137682-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01137682-pasireotide-v1
- Content SHA-256: `56cfe90889206662650c30fbcf7b310266972865f484f6adbcb9d6483a1a02cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01137682 ([`ctg-observation-nct01137682-2018-04-05-ba29e020af3d`](#source-ctg-observation-nct01137682-2018-04-05-ba29e020af3d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01137682 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-04-05, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01137682-2018-04-05-ba29e020af3d`](#source-ctg-observation-nct01137682-2018-04-05-ba29e020af3d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01137682 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-04-05, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01137682-2018-04-05-ba29e020af3d`](#source-ctg-observation-nct01137682-2018-04-05-ba29e020af3d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01137682-2018-04-05-ba29e020af3d`](#source-ctg-observation-nct01137682-2018-04-05-ba29e020af3d))

### Sources

<a id="source-ctg-observation-nct01137682-2018-04-05-ba29e020af3d"></a>
- **ClinicalTrials.gov record NCT01137682 · retained source version 2018-04-05:ba29e020af3d949c8b035f93a03b75d76ce0cc8d50f01c2860caadc327dd89c0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01137682) (`ctg-observation-nct01137682-2018-04-05-ba29e020af3d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01137682." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01137682-pasireotide-v1 SHA-256: 56cfe90889206662650c30fbcf7b310266972865f484f6adbcb9d6483a1a02cd.

---

<a id="clinicaltrials-gov-nct01270321-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01270321

> PeptideScanner retained ClinicalTrials.gov record NCT01270321 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-02-17, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01270321-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-02-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01270321-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01270321-pasireotide-v1
- Content SHA-256: `daaed4e20826c2f4e2f71c9e655ac0fcfdfc6ef42ce84688794342ced4d7b517`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01270321 ([`ctg-observation-nct01270321-2021-02-17-c9ed3429d57b`](#source-ctg-observation-nct01270321-2021-02-17-c9ed3429d57b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01270321 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-02-17, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01270321-2021-02-17-c9ed3429d57b`](#source-ctg-observation-nct01270321-2021-02-17-c9ed3429d57b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01270321 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-02-17, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01270321-2021-02-17-c9ed3429d57b`](#source-ctg-observation-nct01270321-2021-02-17-c9ed3429d57b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01270321-2021-02-17-c9ed3429d57b`](#source-ctg-observation-nct01270321-2021-02-17-c9ed3429d57b))

### Sources

<a id="source-ctg-observation-nct01270321-2021-02-17-c9ed3429d57b"></a>
- **ClinicalTrials.gov record NCT01270321 · retained source version 2021-02-17:c9ed3429d57bed3ca4e6ee925dec2d32f2524a7fe5d689777397c4a32d9e5b85** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01270321) (`ctg-observation-nct01270321-2021-02-17-c9ed3429d57b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01270321." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01270321-pasireotide-v1 SHA-256: daaed4e20826c2f4e2f71c9e655ac0fcfdfc6ef42ce84688794342ced4d7b517.

---

<a id="clinicaltrials-gov-nct01356862-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01356862

> PeptideScanner retained ClinicalTrials.gov record NCT01356862 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01356862-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01356862-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01356862-pasireotide-v1
- Content SHA-256: `9a2c20b5625c027d95ac6c5cb12c8ecea9b4e973ddfd5b961e0a1e640538a6ee`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01356862 ([`ctg-observation-nct01356862-2017-01-25-8b20b04affc1`](#source-ctg-observation-nct01356862-2017-01-25-8b20b04affc1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01356862 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01356862-2017-01-25-8b20b04affc1`](#source-ctg-observation-nct01356862-2017-01-25-8b20b04affc1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01356862 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01356862-2017-01-25-8b20b04affc1`](#source-ctg-observation-nct01356862-2017-01-25-8b20b04affc1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01356862-2017-01-25-8b20b04affc1`](#source-ctg-observation-nct01356862-2017-01-25-8b20b04affc1))

### Sources

<a id="source-ctg-observation-nct01356862-2017-01-25-8b20b04affc1"></a>
- **ClinicalTrials.gov record NCT01356862 · retained source version 2017-01-25:8b20b04affc18fbf474b5415343d8b6274d998aae8f99b28664c81be9be4101f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01356862) (`ctg-observation-nct01356862-2017-01-25-8b20b04affc1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01356862." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01356862-pasireotide-v1 SHA-256: 9a2c20b5625c027d95ac6c5cb12c8ecea9b4e973ddfd5b961e0a1e640538a6ee.

---

<a id="clinicaltrials-gov-nct01385956-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01385956

> PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01385956-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-09-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01385956-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01385956-pasireotide-v1
- Content SHA-256: `b8df8fff2f08d4ffbd4c99aca546ca7ecd80c335fce54bdfc3f5760e797decbd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01385956 ([`ctg-observation-nct01385956-2020-09-28-61998f15e6b6`](#source-ctg-observation-nct01385956-2020-09-28-61998f15e6b6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01385956-2020-09-28-61998f15e6b6`](#source-ctg-observation-nct01385956-2020-09-28-61998f15e6b6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01385956-2020-09-28-61998f15e6b6`](#source-ctg-observation-nct01385956-2020-09-28-61998f15e6b6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01385956-2020-09-28-61998f15e6b6`](#source-ctg-observation-nct01385956-2020-09-28-61998f15e6b6))

### Sources

<a id="source-ctg-observation-nct01385956-2020-09-28-61998f15e6b6"></a>
- **ClinicalTrials.gov record NCT01385956 · retained source version 2020-09-28:61998f15e6b6d7482cf544e20be8e0e8eb565ce9ff87b94f2019615044037d58** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01385956) (`ctg-observation-nct01385956-2020-09-28-61998f15e6b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01385956." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01385956-pasireotide-v1 SHA-256: b8df8fff2f08d4ffbd4c99aca546ca7ecd80c335fce54bdfc3f5760e797decbd.

---

<a id="clinicaltrials-gov-nct01468532-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01468532

> PeptideScanner retained ClinicalTrials.gov record NCT01468532 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-03-25, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01468532-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01468532-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01468532-pasireotide-v1
- Content SHA-256: `ffda1b790794637603f8d166e0d3a3d9fc11e30aebd44101ab84c1e7618f23ee`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01468532 ([`ctg-observation-nct01468532-2021-03-25-06d926bcda91`](#source-ctg-observation-nct01468532-2021-03-25-06d926bcda91))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01468532 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-03-25, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01468532-2021-03-25-06d926bcda91`](#source-ctg-observation-nct01468532-2021-03-25-06d926bcda91))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01468532 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-03-25, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01468532-2021-03-25-06d926bcda91`](#source-ctg-observation-nct01468532-2021-03-25-06d926bcda91))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01468532-2021-03-25-06d926bcda91`](#source-ctg-observation-nct01468532-2021-03-25-06d926bcda91))

### Sources

<a id="source-ctg-observation-nct01468532-2021-03-25-06d926bcda91"></a>
- **ClinicalTrials.gov record NCT01468532 · retained source version 2021-03-25:06d926bcda91cf7d088bc50328ae7e7463ef96a42f5a2e6505693c0c3d2eeada** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01468532) (`ctg-observation-nct01468532-2021-03-25-06d926bcda91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01468532." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01468532-pasireotide-v1 SHA-256: ffda1b790794637603f8d166e0d3a3d9fc11e30aebd44101ab84c1e7618f23ee.

---

<a id="clinicaltrials-gov-nct01469572-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01469572

> PeptideScanner retained ClinicalTrials.gov record NCT01469572 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-10-18, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01469572-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-10-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01469572-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01469572-pasireotide-v1
- Content SHA-256: `8dedfab2e50539da082454bc09dfe0e0f80480cf6633ec992e641076acfae0a6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01469572 ([`ctg-observation-nct01469572-2018-10-18-b0ee7db191ef`](#source-ctg-observation-nct01469572-2018-10-18-b0ee7db191ef))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01469572 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-10-18, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01469572-2018-10-18-b0ee7db191ef`](#source-ctg-observation-nct01469572-2018-10-18-b0ee7db191ef))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01469572 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-10-18, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01469572-2018-10-18-b0ee7db191ef`](#source-ctg-observation-nct01469572-2018-10-18-b0ee7db191ef))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01469572-2018-10-18-b0ee7db191ef`](#source-ctg-observation-nct01469572-2018-10-18-b0ee7db191ef))

### Sources

<a id="source-ctg-observation-nct01469572-2018-10-18-b0ee7db191ef"></a>
- **ClinicalTrials.gov record NCT01469572 · retained source version 2018-10-18:b0ee7db191ef32800f1c135043ddaf3227dd67653ad3bf0a0f38d07eeb1f1208** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01469572) (`ctg-observation-nct01469572-2018-10-18-b0ee7db191ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01469572." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01469572-pasireotide-v1 SHA-256: 8dedfab2e50539da082454bc09dfe0e0f80480cf6633ec992e641076acfae0a6.

---

<a id="clinicaltrials-gov-nct01488487-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01488487

> PeptideScanner retained ClinicalTrials.gov record NCT01488487 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-04-07, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01488487-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01488487-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01488487-pasireotide-v1
- Content SHA-256: `01d174c46d7e3f8eba04c4d786c3cb25602d74f27a2a90f02c3cde7e11f0706d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01488487 ([`ctg-observation-nct01488487-2016-04-07-100f32b048e8`](#source-ctg-observation-nct01488487-2016-04-07-100f32b048e8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01488487 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-04-07, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01488487-2016-04-07-100f32b048e8`](#source-ctg-observation-nct01488487-2016-04-07-100f32b048e8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01488487 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-04-07, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01488487-2016-04-07-100f32b048e8`](#source-ctg-observation-nct01488487-2016-04-07-100f32b048e8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01488487-2016-04-07-100f32b048e8`](#source-ctg-observation-nct01488487-2016-04-07-100f32b048e8))

### Sources

<a id="source-ctg-observation-nct01488487-2016-04-07-100f32b048e8"></a>
- **ClinicalTrials.gov record NCT01488487 · retained source version 2016-04-07:100f32b048e8406c5f2c5ed455bf1b8ca5e013e7d4e4a392994a62e6dabc6f75** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01488487) (`ctg-observation-nct01488487-2016-04-07-100f32b048e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01488487." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01488487-pasireotide-v1 SHA-256: 01d174c46d7e3f8eba04c4d786c3cb25602d74f27a2a90f02c3cde7e11f0706d.

---

<a id="clinicaltrials-gov-nct01620138-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01620138

> PeptideScanner retained ClinicalTrials.gov record NCT01620138 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-08-22, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01620138-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01620138-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01620138-pasireotide-v1
- Content SHA-256: `465a86c65a597dcfe6acc8508ab696fa49bebf8472ac2ccd2fe98efae698ab59`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01620138 ([`ctg-observation-nct01620138-2016-08-22-de5fc901974d`](#source-ctg-observation-nct01620138-2016-08-22-de5fc901974d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01620138 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-08-22, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01620138-2016-08-22-de5fc901974d`](#source-ctg-observation-nct01620138-2016-08-22-de5fc901974d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01620138 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-08-22, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01620138-2016-08-22-de5fc901974d`](#source-ctg-observation-nct01620138-2016-08-22-de5fc901974d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01620138-2016-08-22-de5fc901974d`](#source-ctg-observation-nct01620138-2016-08-22-de5fc901974d))

### Sources

<a id="source-ctg-observation-nct01620138-2016-08-22-de5fc901974d"></a>
- **ClinicalTrials.gov record NCT01620138 · retained source version 2016-08-22:de5fc901974d86c4a92984698215327d40b84f01e5a2b0208671863779ba16f2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01620138) (`ctg-observation-nct01620138-2016-08-22-de5fc901974d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01620138." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01620138-pasireotide-v1 SHA-256: 465a86c65a597dcfe6acc8508ab696fa49bebf8472ac2ccd2fe98efae698ab59.

---

<a id="clinicaltrials-gov-nct01637272-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01637272

> PeptideScanner retained ClinicalTrials.gov record NCT01637272 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-05-10, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01637272-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01637272-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01637272-pasireotide-v1
- Content SHA-256: `d0d788aa8dbcddd72b5e795d8545d8691c95eedc6d4bc262ffdd0dd7d1af3688`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01637272 ([`ctg-observation-nct01637272-2017-05-10-f192c62f51f9`](#source-ctg-observation-nct01637272-2017-05-10-f192c62f51f9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01637272 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-05-10, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01637272-2017-05-10-f192c62f51f9`](#source-ctg-observation-nct01637272-2017-05-10-f192c62f51f9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01637272 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-05-10, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01637272-2017-05-10-f192c62f51f9`](#source-ctg-observation-nct01637272-2017-05-10-f192c62f51f9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01637272-2017-05-10-f192c62f51f9`](#source-ctg-observation-nct01637272-2017-05-10-f192c62f51f9))

### Sources

<a id="source-ctg-observation-nct01637272-2017-05-10-f192c62f51f9"></a>
- **ClinicalTrials.gov record NCT01637272 · retained source version 2017-05-10:f192c62f51f953abfa6ff228548e05364767aca3b1c22bd9a122c1186a12aa38** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01637272) (`ctg-observation-nct01637272-2017-05-10-f192c62f51f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01637272." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01637272-pasireotide-v1 SHA-256: d0d788aa8dbcddd72b5e795d8545d8691c95eedc6d4bc262ffdd0dd7d1af3688.

---

<a id="clinicaltrials-gov-nct01794793-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01794793

> PeptideScanner retained ClinicalTrials.gov record NCT01794793 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01794793-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01794793-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01794793-pasireotide-v1
- Content SHA-256: `8b73c13dfb3203cb8c1b96d8ad4481b7c3776fb2318d5945d18f5d95e61bbfec`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01794793 ([`ctg-observation-nct01794793-2024-10-01-46b2d395c1ec`](#source-ctg-observation-nct01794793-2024-10-01-46b2d395c1ec))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01794793 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01794793-2024-10-01-46b2d395c1ec`](#source-ctg-observation-nct01794793-2024-10-01-46b2d395c1ec))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01794793 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01794793-2024-10-01-46b2d395c1ec`](#source-ctg-observation-nct01794793-2024-10-01-46b2d395c1ec))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01794793-2024-10-01-46b2d395c1ec`](#source-ctg-observation-nct01794793-2024-10-01-46b2d395c1ec))

### Sources

<a id="source-ctg-observation-nct01794793-2024-10-01-46b2d395c1ec"></a>
- **ClinicalTrials.gov record NCT01794793 · retained source version 2024-10-01:46b2d395c1ecd486541dd016b5c3d81d9a182e3873ba7538ec7f630be60a3b4d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01794793) (`ctg-observation-nct01794793-2024-10-01-46b2d395c1ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01794793." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01794793-pasireotide-v1 SHA-256: 8b73c13dfb3203cb8c1b96d8ad4481b7c3776fb2318d5945d18f5d95e61bbfec.

---

<a id="clinicaltrials-gov-nct01895296-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT01895296

> PeptideScanner retained ClinicalTrials.gov record NCT01895296 at 2026-11-15T22:05:38.400Z. Its registry update date was 2013-07-10, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct01895296-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-07-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01895296-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01895296-pasireotide-v1
- Content SHA-256: `bf9d00eeac1286e6c90e98d02767e7135bdc82c9b2c833659f4e8d9fcac57ebd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01895296 ([`ctg-observation-nct01895296-2013-07-10-4ccf1234a79c`](#source-ctg-observation-nct01895296-2013-07-10-4ccf1234a79c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01895296 at 2026-11-15T22:05:38.400Z. Its registry update date was 2013-07-10, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01895296-2013-07-10-4ccf1234a79c`](#source-ctg-observation-nct01895296-2013-07-10-4ccf1234a79c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01895296 at 2026-11-15T22:05:38.400Z. Its registry update date was 2013-07-10, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct01895296-2013-07-10-4ccf1234a79c`](#source-ctg-observation-nct01895296-2013-07-10-4ccf1234a79c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01895296-2013-07-10-4ccf1234a79c`](#source-ctg-observation-nct01895296-2013-07-10-4ccf1234a79c))

### Sources

<a id="source-ctg-observation-nct01895296-2013-07-10-4ccf1234a79c"></a>
- **ClinicalTrials.gov record NCT01895296 · retained source version 2013-07-10:4ccf1234a79cb552175eab3453d2c15649578db172b24d065f9dbe1590ee40a7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01895296) (`ctg-observation-nct01895296-2013-07-10-4ccf1234a79c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01895296." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct01895296-pasireotide-v1 SHA-256: bf9d00eeac1286e6c90e98d02767e7135bdc82c9b2c833659f4e8d9fcac57ebd.

---

<a id="clinicaltrials-gov-nct02021942-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT02021942

> PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct02021942-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02021942-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02021942-pasireotide-v1
- Content SHA-256: `6fd6bf5b5af13fb50372a6441f02bf84f20d9facb358d9f756fbac01e3c83172`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02021942 ([`ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2`](#source-ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2`](#source-ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2`](#source-ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2`](#source-ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2))

### Sources

<a id="source-ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2"></a>
- **ClinicalTrials.gov record NCT02021942 · retained source version 2018-02-05:a9bc0d58c2a2facdffc71dfb3e3b6e6c05eab639e2f5158e5648df087478b83a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02021942) (`ctg-observation-nct02021942-2018-02-05-a9bc0d58c2a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02021942." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02021942-pasireotide-v1 SHA-256: 6fd6bf5b5af13fb50372a6441f02bf84f20d9facb358d9f756fbac01e3c83172.

---

<a id="clinicaltrials-gov-nct02215070-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT02215070

> PeptideScanner retained ClinicalTrials.gov record NCT02215070 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-11-17, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct02215070-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02215070-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02215070-pasireotide-v1
- Content SHA-256: `3ebe4302b37471b8bf93ab04c90f8e93c766d11b8d591e2a1456b2eed1ef2f96`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02215070 ([`ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9`](#source-ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02215070 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-11-17, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9`](#source-ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02215070 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-11-17, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9`](#source-ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9`](#source-ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9))

### Sources

<a id="source-ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9"></a>
- **ClinicalTrials.gov record NCT02215070 · retained source version 2021-11-17:250cf1a3f5c9286c772386b4372c0354a4732d1d225cbd922aef24c6a710a4b4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02215070) (`ctg-observation-nct02215070-2021-11-17-250cf1a3f5c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02215070." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02215070-pasireotide-v1 SHA-256: 3ebe4302b37471b8bf93ab04c90f8e93c766d11b8d591e2a1456b2eed1ef2f96.

---

<a id="clinicaltrials-gov-nct02310269-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT02310269

> PeptideScanner retained ClinicalTrials.gov record NCT02310269 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct02310269-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02310269-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02310269-pasireotide-v1
- Content SHA-256: `abb6224029c35f01ba896ebe31a5efff582be1da42ffeac146d3a07539fab62d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02310269 ([`ctg-observation-nct02310269-2024-10-15-62181a6609bd`](#source-ctg-observation-nct02310269-2024-10-15-62181a6609bd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02310269 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02310269-2024-10-15-62181a6609bd`](#source-ctg-observation-nct02310269-2024-10-15-62181a6609bd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02310269 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02310269-2024-10-15-62181a6609bd`](#source-ctg-observation-nct02310269-2024-10-15-62181a6609bd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02310269-2024-10-15-62181a6609bd`](#source-ctg-observation-nct02310269-2024-10-15-62181a6609bd))

### Sources

<a id="source-ctg-observation-nct02310269-2024-10-15-62181a6609bd"></a>
- **ClinicalTrials.gov record NCT02310269 · retained source version 2024-10-15:62181a6609bd49395a7740bdd2d7db575c81f076690736a266f0109b2ed3731e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02310269) (`ctg-observation-nct02310269-2024-10-15-62181a6609bd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02310269." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02310269-pasireotide-v1 SHA-256: abb6224029c35f01ba896ebe31a5efff582be1da42ffeac146d3a07539fab62d.

---

<a id="clinicaltrials-gov-nct02527993-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT02527993

> PeptideScanner retained ClinicalTrials.gov record NCT02527993 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-03-07, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct02527993-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-03-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02527993-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02527993-pasireotide-v1
- Content SHA-256: `12e0764bd88db5969c36022cea02488800395f649f3eeaf41f8f39a41e404dc3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02527993 ([`ctg-observation-nct02527993-2018-03-07-f401cba76bd5`](#source-ctg-observation-nct02527993-2018-03-07-f401cba76bd5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02527993 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-03-07, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02527993-2018-03-07-f401cba76bd5`](#source-ctg-observation-nct02527993-2018-03-07-f401cba76bd5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02527993 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-03-07, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02527993-2018-03-07-f401cba76bd5`](#source-ctg-observation-nct02527993-2018-03-07-f401cba76bd5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02527993-2018-03-07-f401cba76bd5`](#source-ctg-observation-nct02527993-2018-03-07-f401cba76bd5))

### Sources

<a id="source-ctg-observation-nct02527993-2018-03-07-f401cba76bd5"></a>
- **ClinicalTrials.gov record NCT02527993 · retained source version 2018-03-07:f401cba76bd572c265ca0c8821c87c7c2041fe7d89c1a024050d2e6fcef41616** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02527993) (`ctg-observation-nct02527993-2018-03-07-f401cba76bd5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02527993." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02527993-pasireotide-v1 SHA-256: 12e0764bd88db5969c36022cea02488800395f649f3eeaf41f8f39a41e404dc3.

---

<a id="clinicaltrials-gov-nct02622906-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT02622906

> PeptideScanner retained ClinicalTrials.gov record NCT02622906 at 2026-11-15T22:05:38.400Z. Its registry update date was 2015-12-07, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct02622906-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-12-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02622906-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02622906-pasireotide-v1
- Content SHA-256: `0298c934a66d55c210fb0120447b64478d21c93b01313213642fd631727ea603`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02622906 ([`ctg-observation-nct02622906-2015-12-07-848946a16864`](#source-ctg-observation-nct02622906-2015-12-07-848946a16864))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02622906 at 2026-11-15T22:05:38.400Z. Its registry update date was 2015-12-07, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02622906-2015-12-07-848946a16864`](#source-ctg-observation-nct02622906-2015-12-07-848946a16864))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02622906 at 2026-11-15T22:05:38.400Z. Its registry update date was 2015-12-07, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02622906-2015-12-07-848946a16864`](#source-ctg-observation-nct02622906-2015-12-07-848946a16864))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02622906-2015-12-07-848946a16864`](#source-ctg-observation-nct02622906-2015-12-07-848946a16864))

### Sources

<a id="source-ctg-observation-nct02622906-2015-12-07-848946a16864"></a>
- **ClinicalTrials.gov record NCT02622906 · retained source version 2015-12-07:848946a16864b26a27392fc1d945e8b5adde08618328f3235c9f023c1e298808** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02622906) (`ctg-observation-nct02622906-2015-12-07-848946a16864`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02622906." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02622906-pasireotide-v1 SHA-256: 0298c934a66d55c210fb0120447b64478d21c93b01313213642fd631727ea603.

---

<a id="clinicaltrials-gov-nct02713776-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT02713776

> PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct02713776-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02713776-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02713776-pasireotide-v1
- Content SHA-256: `323e0025085022fac890db0e277460c3ef681b9da529e12783fc313b6e91c62a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02713776 ([`ctg-observation-nct02713776-2025-12-19-edaae00e2f42`](#source-ctg-observation-nct02713776-2025-12-19-edaae00e2f42))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02713776-2025-12-19-edaae00e2f42`](#source-ctg-observation-nct02713776-2025-12-19-edaae00e2f42))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02713776-2025-12-19-edaae00e2f42`](#source-ctg-observation-nct02713776-2025-12-19-edaae00e2f42))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02713776-2025-12-19-edaae00e2f42`](#source-ctg-observation-nct02713776-2025-12-19-edaae00e2f42))

### Sources

<a id="source-ctg-observation-nct02713776-2025-12-19-edaae00e2f42"></a>
- **ClinicalTrials.gov record NCT02713776 · retained source version 2025-12-19:edaae00e2f4294bb9eb9fedcb9c02dceeb811c363531385383824a4e3bb7b0fe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02713776) (`ctg-observation-nct02713776-2025-12-19-edaae00e2f42`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02713776." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02713776-pasireotide-v1 SHA-256: 323e0025085022fac890db0e277460c3ef681b9da529e12783fc313b6e91c62a.

---

<a id="clinicaltrials-gov-nct02775227-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT02775227

> PeptideScanner retained ClinicalTrials.gov record NCT02775227 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-08-24, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct02775227-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-08-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02775227-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02775227-pasireotide-v1
- Content SHA-256: `6c1d9deecffe4d89c88202db1fb9aec4e7809993e6a97868c50f4bee754741b3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02775227 ([`ctg-observation-nct02775227-2020-08-24-57c13113599e`](#source-ctg-observation-nct02775227-2020-08-24-57c13113599e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02775227 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-08-24, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02775227-2020-08-24-57c13113599e`](#source-ctg-observation-nct02775227-2020-08-24-57c13113599e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02775227 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-08-24, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct02775227-2020-08-24-57c13113599e`](#source-ctg-observation-nct02775227-2020-08-24-57c13113599e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02775227-2020-08-24-57c13113599e`](#source-ctg-observation-nct02775227-2020-08-24-57c13113599e))

### Sources

<a id="source-ctg-observation-nct02775227-2020-08-24-57c13113599e"></a>
- **ClinicalTrials.gov record NCT02775227 · retained source version 2020-08-24:57c13113599e039d9903ba887b72b8c69b1d7c4d4c17b256dd26f416f4a3bc7d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02775227) (`ctg-observation-nct02775227-2020-08-24-57c13113599e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02775227." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct02775227-pasireotide-v1 SHA-256: 6c1d9deecffe4d89c88202db1fb9aec4e7809993e6a97868c50f4bee754741b3.

---

<a id="clinicaltrials-gov-nct03103009-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT03103009

> PeptideScanner retained ClinicalTrials.gov record NCT03103009 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-29, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct03103009-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03103009-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct03103009-pasireotide-v1
- Content SHA-256: `c8220730ffeacc6f6fdaac76a1358f7114e5280806826d1604a1b57d64e7b5c5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03103009 ([`ctg-observation-nct03103009-2021-09-29-857ea401e702`](#source-ctg-observation-nct03103009-2021-09-29-857ea401e702))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03103009 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-29, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct03103009-2021-09-29-857ea401e702`](#source-ctg-observation-nct03103009-2021-09-29-857ea401e702))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03103009 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-29, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct03103009-2021-09-29-857ea401e702`](#source-ctg-observation-nct03103009-2021-09-29-857ea401e702))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03103009-2021-09-29-857ea401e702`](#source-ctg-observation-nct03103009-2021-09-29-857ea401e702))

### Sources

<a id="source-ctg-observation-nct03103009-2021-09-29-857ea401e702"></a>
- **ClinicalTrials.gov record NCT03103009 · retained source version 2021-09-29:857ea401e702f5fa87f36719bcca6b08e1c6391a907cc538333f74ba324b95ee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03103009) (`ctg-observation-nct03103009-2021-09-29-857ea401e702`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03103009." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct03103009-pasireotide-v1 SHA-256: c8220730ffeacc6f6fdaac76a1358f7114e5280806826d1604a1b57d64e7b5c5.

---

<a id="clinicaltrials-gov-nct03847207-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT03847207

> PeptideScanner retained ClinicalTrials.gov record NCT03847207 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-02-19, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct03847207-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03847207-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct03847207-pasireotide-v1
- Content SHA-256: `95f9aafdd02042d57fee51b59532e8f328885e43ae413e8f30a328c3628b7b4b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03847207 ([`ctg-observation-nct03847207-2025-02-19-6064ac3f28ea`](#source-ctg-observation-nct03847207-2025-02-19-6064ac3f28ea))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03847207 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-02-19, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct03847207-2025-02-19-6064ac3f28ea`](#source-ctg-observation-nct03847207-2025-02-19-6064ac3f28ea))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03847207 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-02-19, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct03847207-2025-02-19-6064ac3f28ea`](#source-ctg-observation-nct03847207-2025-02-19-6064ac3f28ea))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03847207-2025-02-19-6064ac3f28ea`](#source-ctg-observation-nct03847207-2025-02-19-6064ac3f28ea))

### Sources

<a id="source-ctg-observation-nct03847207-2025-02-19-6064ac3f28ea"></a>
- **ClinicalTrials.gov record NCT03847207 · retained source version 2025-02-19:6064ac3f28ea8ea6ab8f237aae54124635da23ecbe7390546d77a687b806cb1d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03847207) (`ctg-observation-nct03847207-2025-02-19-6064ac3f28ea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03847207." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct03847207-pasireotide-v1 SHA-256: 95f9aafdd02042d57fee51b59532e8f328885e43ae413e8f30a328c3628b7b4b.

---

<a id="clinicaltrials-gov-nct05928390-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT05928390

> PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct05928390-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05928390-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct05928390-pasireotide-v1
- Content SHA-256: `5fc643c6e936f6043efa28195c4ebb88e2739e071a1dbaa5d462b087e3f87f3d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05928390 ([`ctg-observation-nct05928390-2026-09-17-ad1a65100869`](#source-ctg-observation-nct05928390-2026-09-17-ad1a65100869))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct05928390-2026-09-17-ad1a65100869`](#source-ctg-observation-nct05928390-2026-09-17-ad1a65100869))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct05928390-2026-09-17-ad1a65100869`](#source-ctg-observation-nct05928390-2026-09-17-ad1a65100869))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05928390-2026-09-17-ad1a65100869`](#source-ctg-observation-nct05928390-2026-09-17-ad1a65100869))

### Sources

<a id="source-ctg-observation-nct05928390-2026-09-17-ad1a65100869"></a>
- **ClinicalTrials.gov record NCT05928390 · retained source version 2026-09-17:ad1a65100869ba22061a40abfd3519d254984d7b8f59a6e2964356788b6725b5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05928390) (`ctg-observation-nct05928390-2026-09-17-ad1a65100869`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05928390." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct05928390-pasireotide-v1 SHA-256: 5fc643c6e936f6043efa28195c4ebb88e2739e071a1dbaa5d462b087e3f87f3d.

---

<a id="clinicaltrials-gov-nct06295952-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT06295952

> PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct06295952-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06295952-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct06295952-pasireotide-v1
- Content SHA-256: `b91d0b5eb5f0c5064365b508a24c3a66396c911fabb17cb5f62c1dd22d343f01`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06295952 ([`ctg-observation-nct06295952-2026-03-04-7991c662cf88`](#source-ctg-observation-nct06295952-2026-03-04-7991c662cf88))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct06295952-2026-03-04-7991c662cf88`](#source-ctg-observation-nct06295952-2026-03-04-7991c662cf88))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct06295952-2026-03-04-7991c662cf88`](#source-ctg-observation-nct06295952-2026-03-04-7991c662cf88))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06295952-2026-03-04-7991c662cf88`](#source-ctg-observation-nct06295952-2026-03-04-7991c662cf88))

### Sources

<a id="source-ctg-observation-nct06295952-2026-03-04-7991c662cf88"></a>
- **ClinicalTrials.gov record NCT06295952 · retained source version 2026-03-04:7991c662cf884e0aad43f9d1f1d9bf061177afee3bc52018a1dc47626914e436** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06295952) (`ctg-observation-nct06295952-2026-03-04-7991c662cf88`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06295952." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct06295952-pasireotide-v1 SHA-256: b91d0b5eb5f0c5064365b508a24c3a66396c911fabb17cb5f62c1dd22d343f01.

---

<a id="clinicaltrials-gov-nct06456359-pasireotide-v1"></a>

## ClinicalTrials.gov record NCT06456359

> PeptideScanner retained ClinicalTrials.gov record NCT06456359 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-01-13, and PeptideScanner's reviewed identity mapping was pasireotide.

- Evidence object: `story:clinicaltrials-gov-nct06456359-pasireotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-01-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06456359-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct06456359-pasireotide-v1
- Content SHA-256: `b58c3ccab7178be900b0529593b622aa5cc4ba8e9c6a4a29140ef161bdc3898f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06456359 ([`ctg-observation-nct06456359-2025-01-13-fb91ac9f0206`](#source-ctg-observation-nct06456359-2025-01-13-fb91ac9f0206))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06456359 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-01-13, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct06456359-2025-01-13-fb91ac9f0206`](#source-ctg-observation-nct06456359-2025-01-13-fb91ac9f0206))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06456359 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-01-13, and PeptideScanner's reviewed identity mapping was pasireotide. ([`ctg-observation-nct06456359-2025-01-13-fb91ac9f0206`](#source-ctg-observation-nct06456359-2025-01-13-fb91ac9f0206))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06456359-2025-01-13-fb91ac9f0206`](#source-ctg-observation-nct06456359-2025-01-13-fb91ac9f0206))

### Sources

<a id="source-ctg-observation-nct06456359-2025-01-13-fb91ac9f0206"></a>
- **ClinicalTrials.gov record NCT06456359 · retained source version 2025-01-13:fb91ac9f020695d40cb9185782d7ac42c49b8a5c27de3d7b0f2b52cdc03cef69** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06456359) (`ctg-observation-nct06456359-2025-01-13-fb91ac9f0206`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06456359." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#clinicaltrials-gov-nct06456359-pasireotide-v1 SHA-256: b58c3ccab7178be900b0529593b622aa5cc4ba8e9c6a4a29140ef161bdc3898f.

---

<a id="fda-drugs-nda200677-v1"></a>

## Drugs@FDA application NDA200677

> The official Drugs@FDA dataset lists original submission 1 for NDA 200677 with status AP dated 2012-12-14, and names pasireotide diaspartate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda200677:v1`
- Evidence domain: Regulatory
- Date in source: 2012-12-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda200677/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#fda-drugs-nda200677-v1
- Content SHA-256: `6947713b4f70cf263ee5799e1ff96b1e674bf640b397fbdd44cc0e298290bc98`

### Claims and source pins

#### Headline

Drugs@FDA application NDA200677 ([`fda-drugs-nda200677-2012-12-14-05cb18efe5d6`](#source-fda-drugs-nda200677-2012-12-14-05cb18efe5d6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 200677 with status AP dated 2012-12-14, and names pasireotide diaspartate among the application record's active ingredients. ([`fda-drugs-nda200677-2012-12-14-05cb18efe5d6`](#source-fda-drugs-nda200677-2012-12-14-05cb18efe5d6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 200677 with status AP dated 2012-12-14, and names pasireotide diaspartate among the application record's active ingredients. ([`fda-drugs-nda200677-2012-12-14-05cb18efe5d6`](#source-fda-drugs-nda200677-2012-12-14-05cb18efe5d6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda200677-2012-12-14-05cb18efe5d6`](#source-fda-drugs-nda200677-2012-12-14-05cb18efe5d6))

### Sources

<a id="source-fda-drugs-nda200677-2012-12-14-05cb18efe5d6"></a>
- **Drugs@FDA application NDA200677 · original submission status AP · 2012-12-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA200677%22&limit=1) (`fda-drugs-nda200677-2012-12-14-05cb18efe5d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA200677." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#fda-drugs-nda200677-v1 SHA-256: 6947713b4f70cf263ee5799e1ff96b1e674bf640b397fbdd44cc0e298290bc98.

---

<a id="federal-register-2012-25483-v1"></a>

## Federal Register notice 2012-25483

> The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.

- Evidence object: `story:federal-register-2012-25483:v1`
- Evidence domain: Regulatory
- Date in source: 2012-10-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-25483/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#federal-register-2012-25483-v1
- Content SHA-256: `04766fc80a5dcf4ec0766ab2e89c826e93cd67310ca3c615373f4be84d76d223`

### Claims and source pins

#### Headline

Federal Register notice 2012-25483 ([`federal-register-2012-25483-c0e488f5d183`](#source-federal-register-2012-25483-c0e488f5d183))

#### Summary

The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide. ([`federal-register-2012-25483-c0e488f5d183`](#source-federal-register-2012-25483-c0e488f5d183))

#### Paragraph 1

The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide. ([`federal-register-2012-25483-c0e488f5d183`](#source-federal-register-2012-25483-c0e488f5d183))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-25483-c0e488f5d183`](#source-federal-register-2012-25483-c0e488f5d183))

### Sources

<a id="source-federal-register-2012-25483-c0e488f5d183"></a>
- **Federal Register notice 2012-25483 · published 2012-10-17 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-10-17/pdf/2012-25483.pdf) (`federal-register-2012-25483-c0e488f5d183`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-25483." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#federal-register-2012-25483-v1 SHA-256: 04766fc80a5dcf4ec0766ab2e89c826e93cd67310ca3c615373f4be84d76d223.

---

<a id="federal-register-2015-10994-v1"></a>

## Federal Register notice 2015-10994

> The Federal Register published notice 2015-10994, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.

- Evidence object: `story:federal-register-2015-10994:v1`
- Evidence domain: Regulatory
- Date in source: 2015-05-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2015-10994/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#federal-register-2015-10994-v1
- Content SHA-256: `be5f0061b0755102902653ca4355224f54ea876fe7e86757f3e141df387a985e`

### Claims and source pins

#### Headline

Federal Register notice 2015-10994 ([`federal-register-2015-10994-5c95cbd39113`](#source-federal-register-2015-10994-5c95cbd39113))

#### Summary

The Federal Register published notice 2015-10994, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide. ([`federal-register-2015-10994-5c95cbd39113`](#source-federal-register-2015-10994-5c95cbd39113))

#### Paragraph 1

The Federal Register published notice 2015-10994, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide. ([`federal-register-2015-10994-5c95cbd39113`](#source-federal-register-2015-10994-5c95cbd39113))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2015-10994-5c95cbd39113`](#source-federal-register-2015-10994-5c95cbd39113))

### Sources

<a id="source-federal-register-2015-10994-5c95cbd39113"></a>
- **Federal Register notice 2015-10994 · published 2015-05-07 · Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10994.pdf) (`federal-register-2015-10994-5c95cbd39113`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2015-10994." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#federal-register-2015-10994-v1 SHA-256: be5f0061b0755102902653ca4355224f54ea876fe7e86757f3e141df387a985e.

---

<a id="pubmed-pmid-18957506-pasireotide-v1"></a>

## Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

> PubMed lists PMID 18957506 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2008-10-28 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18957506-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18957506-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-18957506-pasireotide-v1
- Content SHA-256: `be9ac9789c5aa7364ca9c98e6ad0cf8786b0284b14044f1559884a08671f16e7`

### Claims and source pins

#### Headline

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. ([`pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c`](#source-pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c))

#### Summary

PubMed lists PMID 18957506 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2008-10-28 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c`](#source-pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c))

#### Paragraph 1

PubMed lists PMID 18957506 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2008-10-28 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c`](#source-pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c`](#source-pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c))

### Sources

<a id="source-pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c"></a>
- **Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. · retained source version 1:2022-03-09:current:fa88dfa4d63cf149d5cb955f57737e6529d9995b99f69f0b33d9efa89845a52e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18957506/) (`pubmed-observation-pmid-18957506-2022-03-09-fa88dfa4d63c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-18957506-pasireotide-v1 SHA-256: be9ac9789c5aa7364ca9c98e6ad0cf8786b0284b14044f1559884a08671f16e7.

---

<a id="pubmed-pmid-20463350-pasireotide-v1"></a>

## Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

> PubMed lists PMID 20463350 in The New England journal of medicine as Clinical Trial, Letter, Multicenter Study, with publication-date metadata of 2010-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20463350-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20463350-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-20463350-pasireotide-v1
- Content SHA-256: `24cfe5fd4802d9b9c8a095b07d86676b052ecee0beda862b8442957699cb3df9`

### Claims and source pins

#### Headline

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. ([`pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54`](#source-pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54))

#### Summary

PubMed lists PMID 20463350 in The New England journal of medicine as Clinical Trial, Letter, Multicenter Study, with publication-date metadata of 2010-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54`](#source-pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54))

#### Paragraph 1

PubMed lists PMID 20463350 in The New England journal of medicine as Clinical Trial, Letter, Multicenter Study, with publication-date metadata of 2010-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54`](#source-pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54`](#source-pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54))

### Sources

<a id="source-pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54"></a>
- **Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. · retained source version 1:2022-03-15:current:d1ae93e70c548af83194eb4ae280d23c54e8b5d971f83b9332567d5aa536c402** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20463350/) (`pubmed-observation-pmid-20463350-2022-03-15-d1ae93e70c54`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-20463350-pasireotide-v1 SHA-256: 24cfe5fd4802d9b9c8a095b07d86676b052ecee0beda862b8442957699cb3df9.

---

<a id="pubmed-pmid-20533892-pasireotide-v1"></a>

## Pasireotide for the treatment of Cushing's disease.

> PubMed lists PMID 20533892 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2010-07 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20533892-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-11-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20533892-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-20533892-pasireotide-v1
- Content SHA-256: `b299616e535ed98e5fdc8e77c0e2ff075670a08b92e8e310178c96a212ab649f`

### Claims and source pins

#### Headline

Pasireotide for the treatment of Cushing's disease. ([`pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32`](#source-pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32))

#### Summary

PubMed lists PMID 20533892 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2010-07 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32`](#source-pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32))

#### Paragraph 1

PubMed lists PMID 20533892 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2010-07 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32`](#source-pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32`](#source-pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32))

### Sources

<a id="source-pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32"></a>
- **Pasireotide for the treatment of Cushing's disease. · retained source version 1:2014-11-20:current:36ed7cac2f32fcde87d37dcc893d75c8b8a6bcadd8c6a7fcb673ce1521c1bc5f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20533892/) (`pubmed-observation-pmid-20533892-2014-11-20-36ed7cac2f32`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide for the treatment of Cushing's disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-20533892-pasireotide-v1 SHA-256: b299616e535ed98e5fdc8e77c0e2ff075670a08b92e8e310178c96a212ab649f.

---

<a id="pubmed-pmid-23228667-pasireotide-v1"></a>

## Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.

> PubMed lists PMID 23228667 in Diabetes & metabolism as Journal Article, Review, with publication-date metadata of 2012-12-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23228667-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23228667-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23228667-pasireotide-v1
- Content SHA-256: `38aa1444d15f42ae5748a2ebfabb9be4b4a41a0d982ed1e97ae8503983003f48`

### Claims and source pins

#### Headline

Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. ([`pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8`](#source-pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8))

#### Summary

PubMed lists PMID 23228667 in Diabetes & metabolism as Journal Article, Review, with publication-date metadata of 2012-12-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8`](#source-pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8))

#### Paragraph 1

PubMed lists PMID 23228667 in Diabetes & metabolism as Journal Article, Review, with publication-date metadata of 2012-12-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8`](#source-pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8`](#source-pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8))

### Sources

<a id="source-pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8"></a>
- **Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. · retained source version 1:2026-01-28:current:ca4e23402ec85f330150d1f2aa45a1f1b4fc0d63f6cd63bf59d096c0db75cfa3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23228667/) (`pubmed-observation-pmid-23228667-2026-01-28-ca4e23402ec8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23228667-pasireotide-v1 SHA-256: 38aa1444d15f42ae5748a2ebfabb9be4b4a41a0d982ed1e97ae8503983003f48.

---

<a id="pubmed-pmid-23605695-pasireotide-v1"></a>

## Pasireotide: a review of its use in Cushing's disease.

> PubMed lists PMID 23605695 in Drugs as Journal Article, Review, with publication-date metadata of 2013-05 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23605695-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23605695-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23605695-pasireotide-v1
- Content SHA-256: `1d6ef0c4da712707f37008421d39179ca4d77d7e00cf577dfad5b79c2cefbc2b`

### Claims and source pins

#### Headline

Pasireotide: a review of its use in Cushing's disease. ([`pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1`](#source-pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1))

#### Summary

PubMed lists PMID 23605695 in Drugs as Journal Article, Review, with publication-date metadata of 2013-05 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1`](#source-pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1))

#### Paragraph 1

PubMed lists PMID 23605695 in Drugs as Journal Article, Review, with publication-date metadata of 2013-05 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1`](#source-pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1`](#source-pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1))

### Sources

<a id="source-pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1"></a>
- **Pasireotide: a review of its use in Cushing's disease. · retained source version 1:2026-10-11:current:b5eefefc81f19152c7deca52760c5911a329d61a6202b3b86542caf6e19765ff** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23605695/) (`pubmed-observation-pmid-23605695-2026-10-11-b5eefefc81f1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide: a review of its use in Cushing's disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23605695-pasireotide-v1 SHA-256: 1d6ef0c4da712707f37008421d39179ca4d77d7e00cf577dfad5b79c2cefbc2b.

---

<a id="pubmed-pmid-23669783-pasireotide-v1"></a>

## Pasireoride (Signifor) for Cushing's disease.

> PubMed lists PMID 23669783 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2013-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23669783-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-11-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23669783-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23669783-pasireotide-v1
- Content SHA-256: `de4f27f757d61b1c93050c9619ec0847f9221c6c81df51158201cfeef4417db1`

### Claims and source pins

#### Headline

Pasireoride (Signifor) for Cushing's disease. ([`pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e`](#source-pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e))

#### Summary

PubMed lists PMID 23669783 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2013-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e`](#source-pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e))

#### Paragraph 1

PubMed lists PMID 23669783 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2013-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e`](#source-pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e`](#source-pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e))

### Sources

<a id="source-pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e"></a>
- **Pasireoride (Signifor) for Cushing's disease. · retained source version 1:2014-11-20:current:aa5b029d1e1e2680128ce2e1cf1f1e4b1a522fc3ce3843fad46d3832ae323d28** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23669783/) (`pubmed-observation-pmid-23669783-2014-11-20-aa5b029d1e1e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireoride (Signifor) for Cushing's disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23669783-pasireotide-v1 SHA-256: de4f27f757d61b1c93050c9619ec0847f9221c6c81df51158201cfeef4417db1.

---

<a id="pubmed-pmid-23680921-pasireotide-v1"></a>

## Assessment of the absorption, metabolism and excretion of \[¹⁴C\]pasireotide in healthy volunteers using accelerator mass spectrometry.

> PubMed lists PMID 23680921 in Cancer chemotherapy and pharmacology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23680921-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-11-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23680921-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23680921-pasireotide-v1
- Content SHA-256: `281c734aeeec72e1a7131b7fc9766039aebff07e9dffa695d22179bf00583c83`

### Claims and source pins

#### Headline

Assessment of the absorption, metabolism and excretion of \[¹⁴C\]pasireotide in healthy volunteers using accelerator mass spectrometry. ([`pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c`](#source-pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c))

#### Summary

PubMed lists PMID 23680921 in Cancer chemotherapy and pharmacology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c`](#source-pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c))

#### Paragraph 1

PubMed lists PMID 23680921 in Cancer chemotherapy and pharmacology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c`](#source-pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c`](#source-pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c))

### Sources

<a id="source-pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c"></a>
- **Assessment of the absorption, metabolism and excretion of \[¹⁴C\]pasireotide in healthy volunteers using accelerator mass spectrometry. · retained source version 1:2014-11-20:current:60046ecb5b0c39f7d90987d6688ef4f7dad5230b3ba0b54898adcd7370d95607** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23680921/) (`pubmed-observation-pmid-23680921-2014-11-20-60046ecb5b0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Assessment of the absorption, metabolism and excretion of \[¹⁴C\]pasireotide in healthy volunteers using accelerator mass spectrometry." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-23680921-pasireotide-v1 SHA-256: 281c734aeeec72e1a7131b7fc9766039aebff07e9dffa695d22179bf00583c83.

---

<a id="pubmed-pmid-24126229-pasireotide-v1"></a>

## Pasireotide and mifepristone: new options in the medical management of Cushing's disease.

> PubMed lists PMID 24126229 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-01 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24126229-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24126229-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-24126229-pasireotide-v1
- Content SHA-256: `9fa168647b53528a2122ae10d63731e4dec1099c75c1da01c12e550e2efac6ef`

### Claims and source pins

#### Headline

Pasireotide and mifepristone: new options in the medical management of Cushing's disease. ([`pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3`](#source-pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3))

#### Summary

PubMed lists PMID 24126229 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-01 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3`](#source-pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3))

#### Paragraph 1

PubMed lists PMID 24126229 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-01 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3`](#source-pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3`](#source-pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3))

### Sources

<a id="source-pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3"></a>
- **Pasireotide and mifepristone: new options in the medical management of Cushing's disease. · retained source version 1:2021-02-04:current:2e5e3acd71e37c0b5b866aadff8cf8dbc742ca5633ea74d3726a4af98d3f1830** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24126229/) (`pubmed-observation-pmid-24126229-2021-02-04-2e5e3acd71e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide and mifepristone: new options in the medical management of Cushing's disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-24126229-pasireotide-v1 SHA-256: 9fa168647b53528a2122ae10d63731e4dec1099c75c1da01c12e550e2efac6ef.

---

<a id="pubmed-pmid-24287689-pasireotide-v1"></a>

## Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.

> PubMed lists PMID 24287689 in Pituitary as Case Reports, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24287689-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24287689-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-24287689-pasireotide-v1
- Content SHA-256: `c70156c7ea80ace3bdcf6d54f8090605fd35bda3df95d23dc61ee1fd1c690f29`

### Claims and source pins

#### Headline

Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. ([`pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f`](#source-pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f))

#### Summary

PubMed lists PMID 24287689 in Pituitary as Case Reports, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f`](#source-pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f))

#### Paragraph 1

PubMed lists PMID 24287689 in Pituitary as Case Reports, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f`](#source-pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f`](#source-pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f))

### Sources

<a id="source-pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f"></a>
- **Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. · retained source version 1:2022-03-09:current:61cec8f8ab4fab0a961a247379f611dbbcf68c601da45902af9017bf84a67652** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24287689/) (`pubmed-observation-pmid-24287689-2022-03-09-61cec8f8ab4f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-24287689-pasireotide-v1 SHA-256: c70156c7ea80ace3bdcf6d54f8090605fd35bda3df95d23dc61ee1fd1c690f29.

---

<a id="pubmed-pmid-25003365-pasireotide-v1"></a>

## Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.

> PubMed lists PMID 25003365 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-07-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25003365-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-09-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25003365-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-25003365-pasireotide-v1
- Content SHA-256: `164373ed229467ef4e545a44dfdfb7eab623467f88309203b1dae4c38450e719`

### Claims and source pins

#### Headline

Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience. ([`pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e`](#source-pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e))

#### Summary

PubMed lists PMID 25003365 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-07-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e`](#source-pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e))

#### Paragraph 1

PubMed lists PMID 25003365 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-07-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e`](#source-pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e`](#source-pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e))

### Sources

<a id="source-pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e"></a>
- **Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience. · retained source version 1:2014-09-18:current:4784d3e1d63ed90eb9beb044acadba48c6e707c01609fe9ffa49e86a2144c362** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25003365/) (`pubmed-observation-pmid-25003365-2014-09-18-4784d3e1d63e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-25003365-pasireotide-v1 SHA-256: 164373ed229467ef4e545a44dfdfb7eab623467f88309203b1dae4c38450e719.

---

<a id="pubmed-pmid-25613083-pasireotide-v1"></a>

## Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.

> PubMed lists PMID 25613083 in Investigational new drugs as Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2015-01-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25613083-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25613083-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-25613083-pasireotide-v1
- Content SHA-256: `46dbb231965081f569919c1f5cc9f475c42f4d6f13c406053ed41cb130f6d8ef`

### Claims and source pins

#### Headline

Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. ([`pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9`](#source-pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9))

#### Summary

PubMed lists PMID 25613083 in Investigational new drugs as Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2015-01-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9`](#source-pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9))

#### Paragraph 1

PubMed lists PMID 25613083 in Investigational new drugs as Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2015-01-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9`](#source-pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9`](#source-pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9))

### Sources

<a id="source-pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9"></a>
- **Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. · retained source version 1:2022-03-11:current:32b11f3f3ea970e9952cb8854d353d52791472d9bbcb802096772e8f7eb9de07** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25613083/) (`pubmed-observation-pmid-25613083-2022-03-11-32b11f3f3ea9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-25613083-pasireotide-v1 SHA-256: 46dbb231965081f569919c1f5cc9f475c42f4d6f13c406053ed41cb130f6d8ef.

---

<a id="pubmed-pmid-26275531-pasireotide-v1"></a>

## Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.

> PubMed lists PMID 26275531 in Investigational new drugs as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-08-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26275531-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26275531-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-26275531-pasireotide-v1
- Content SHA-256: `a901731f13ad9a37c967d3b27278e92f68258ef60ad94ef585912bf1f01e6094`

### Claims and source pins

#### Headline

Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. ([`pubmed-observation-pmid-26275531-2021-02-16-17864179dc69`](#source-pubmed-observation-pmid-26275531-2021-02-16-17864179dc69))

#### Summary

PubMed lists PMID 26275531 in Investigational new drugs as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-08-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26275531-2021-02-16-17864179dc69`](#source-pubmed-observation-pmid-26275531-2021-02-16-17864179dc69))

#### Paragraph 1

PubMed lists PMID 26275531 in Investigational new drugs as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-08-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26275531-2021-02-16-17864179dc69`](#source-pubmed-observation-pmid-26275531-2021-02-16-17864179dc69))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26275531-2021-02-16-17864179dc69`](#source-pubmed-observation-pmid-26275531-2021-02-16-17864179dc69))

### Sources

<a id="source-pubmed-observation-pmid-26275531-2021-02-16-17864179dc69"></a>
- **Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. · retained source version 1:2021-02-16:current:17864179dc69980f4ec860ac00c9bcaec6d7abf9e8a02af34106272b75fcab50** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26275531/) (`pubmed-observation-pmid-26275531-2021-02-16-17864179dc69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-26275531-pasireotide-v1 SHA-256: a901731f13ad9a37c967d3b27278e92f68258ef60ad94ef585912bf1f01e6094.

---

<a id="pubmed-pmid-26808354-pasireotide-v1"></a>

## Pasireotide for the treatment of acromegaly.

> PubMed lists PMID 26808354 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2016-02-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26808354-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26808354-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-26808354-pasireotide-v1
- Content SHA-256: `1ce8509e9f15692a89836d0802d3f1c3b4c553625e9538ebec55c177857696dc`

### Claims and source pins

#### Headline

Pasireotide for the treatment of acromegaly. ([`pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8`](#source-pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8))

#### Summary

PubMed lists PMID 26808354 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2016-02-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8`](#source-pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8))

#### Paragraph 1

PubMed lists PMID 26808354 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2016-02-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8`](#source-pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8`](#source-pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8))

### Sources

<a id="source-pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8"></a>
- **Pasireotide for the treatment of acromegaly. · retained source version 1:2022-03-10:current:03de4b0fffb8c7d4cddf99242d37a130a79d710b18b8f2d75b6965d36b2de07f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26808354/) (`pubmed-observation-pmid-26808354-2022-03-10-03de4b0fffb8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide for the treatment of acromegaly." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-26808354-pasireotide-v1 SHA-256: 1ce8509e9f15692a89836d0802d3f1c3b4c553625e9538ebec55c177857696dc.

---

<a id="pubmed-pmid-27473537-pasireotide-v1"></a>

## Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.

> PubMed lists PMID 27473537 in Drugs as Journal Article, Review, with publication-date metadata of 2016-09 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27473537-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27473537-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-27473537-pasireotide-v1
- Content SHA-256: `38ecbabe5886235f8cac1f74ba6614f5fc5e630656b7537f22fb863c1cd1b87d`

### Claims and source pins

#### Headline

Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. ([`pubmed-observation-pmid-27473537-2026-01-27-b069c6037257`](#source-pubmed-observation-pmid-27473537-2026-01-27-b069c6037257))

#### Summary

PubMed lists PMID 27473537 in Drugs as Journal Article, Review, with publication-date metadata of 2016-09 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27473537-2026-01-27-b069c6037257`](#source-pubmed-observation-pmid-27473537-2026-01-27-b069c6037257))

#### Paragraph 1

PubMed lists PMID 27473537 in Drugs as Journal Article, Review, with publication-date metadata of 2016-09 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27473537-2026-01-27-b069c6037257`](#source-pubmed-observation-pmid-27473537-2026-01-27-b069c6037257))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27473537-2026-01-27-b069c6037257`](#source-pubmed-observation-pmid-27473537-2026-01-27-b069c6037257))

### Sources

<a id="source-pubmed-observation-pmid-27473537-2026-01-27-b069c6037257"></a>
- **Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. · retained source version 1:2026-01-27:current:b069c6037257e348a830f298fe12a52d9c5ef57c36ee9d3b53e9530b5e3e45e6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27473537/) (`pubmed-observation-pmid-27473537-2026-01-27-b069c6037257`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-27473537-pasireotide-v1 SHA-256: 38ecbabe5886235f8cac1f74ba6614f5fc5e630656b7537f22fb863c1cd1b87d.

---

<a id="pubmed-pmid-29396758-pasireotide-v1"></a>

## Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

> PubMed lists PMID 29396758 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2018-02-02 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29396758-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-01-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29396758-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-29396758-pasireotide-v1
- Content SHA-256: `df19acbbddd7df9346f3cbb324ca2f16bfedd788d0b7224d85f6f210c8aa96a8`

### Claims and source pins

#### Headline

Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide. ([`pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f`](#source-pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f))

#### Summary

PubMed lists PMID 29396758 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2018-02-02 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f`](#source-pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f))

#### Paragraph 1

PubMed lists PMID 29396758 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2018-02-02 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f`](#source-pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f`](#source-pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f))

### Sources

<a id="source-pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f"></a>
- **Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide. · retained source version 1:2019-01-09:current:67ae88566f3fd47ff3c4de6896464fba48ad525cf7fb17617ecf0ba7f1f10546** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29396758/) (`pubmed-observation-pmid-29396758-2019-01-09-67ae88566f3f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-29396758-pasireotide-v1 SHA-256: df19acbbddd7df9346f3cbb324ca2f16bfedd788d0b7224d85f6f210c8aa96a8.

---

<a id="pubmed-pmid-29534939-pasireotide-v1"></a>

## Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.

> PubMed lists PMID 29534939 in Clinical genitourinary cancer as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-02-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29534939-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-02-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29534939-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-29534939-pasireotide-v1
- Content SHA-256: `3eddfea3892c39d398c5ae40691c025f5be1f5f9e6288236dc85f608c9d6ae9a`

### Claims and source pins

#### Headline

Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. ([`pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51`](#source-pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51))

#### Summary

PubMed lists PMID 29534939 in Clinical genitourinary cancer as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-02-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51`](#source-pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51))

#### Paragraph 1

PubMed lists PMID 29534939 in Clinical genitourinary cancer as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-02-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51`](#source-pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51`](#source-pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51))

### Sources

<a id="source-pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51"></a>
- **Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. · retained source version 1:2019-02-15:current:75d4e348ac5176a64779b7e9240abc893ca3893ebe168cf7b3c57e9759b57d59** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29534939/) (`pubmed-observation-pmid-29534939-2019-02-15-75d4e348ac51`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-29534939-pasireotide-v1 SHA-256: 3eddfea3892c39d398c5ae40691c025f5be1f5f9e6288236dc85f608c9d6ae9a.

---

<a id="pubmed-pmid-30608534-pasireotide-v1"></a>

## How to Position Pasireotide LAR Treatment in Acromegaly.

> PubMed lists PMID 30608534 in The Journal of clinical endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2019-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30608534-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-05-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30608534-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-30608534-pasireotide-v1
- Content SHA-256: `9ada0fd632983e65e6c79a47de47184e660417bb3ab4bbbd7d7c0915ff2e75ab`

### Claims and source pins

#### Headline

How to Position Pasireotide LAR Treatment in Acromegaly. ([`pubmed-observation-pmid-30608534-2020-05-05-780264ddff82`](#source-pubmed-observation-pmid-30608534-2020-05-05-780264ddff82))

#### Summary

PubMed lists PMID 30608534 in The Journal of clinical endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2019-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30608534-2020-05-05-780264ddff82`](#source-pubmed-observation-pmid-30608534-2020-05-05-780264ddff82))

#### Paragraph 1

PubMed lists PMID 30608534 in The Journal of clinical endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2019-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30608534-2020-05-05-780264ddff82`](#source-pubmed-observation-pmid-30608534-2020-05-05-780264ddff82))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30608534-2020-05-05-780264ddff82`](#source-pubmed-observation-pmid-30608534-2020-05-05-780264ddff82))

### Sources

<a id="source-pubmed-observation-pmid-30608534-2020-05-05-780264ddff82"></a>
- **How to Position Pasireotide LAR Treatment in Acromegaly. · retained source version 1:2020-05-05:current:780264ddff82dbaaf78e82dcbe5c7c5e7703291ebe853d3c7b9725b8cdb4fd46** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30608534/) (`pubmed-observation-pmid-30608534-2020-05-05-780264ddff82`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "How to Position Pasireotide LAR Treatment in Acromegaly." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-30608534-pasireotide-v1 SHA-256: 9ada0fd632983e65e6c79a47de47184e660417bb3ab4bbbd7d7c0915ff2e75ab.

---

<a id="pubmed-pmid-32843370-pasireotide-v1"></a>

## Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

> PubMed lists PMID 32843370 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-08-25 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32843370-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-08-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32843370-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-32843370-pasireotide-v1
- Content SHA-256: `c769c897c4ed4ef5cb14726837ce35efe45a463f7e16dfdf400f5e04ac839d78`

### Claims and source pins

#### Headline

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. ([`pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0`](#source-pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0))

#### Summary

PubMed lists PMID 32843370 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-08-25 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0`](#source-pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0))

#### Paragraph 1

PubMed lists PMID 32843370 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-08-25 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0`](#source-pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0`](#source-pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0))

### Sources

<a id="source-pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0"></a>
- **Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. · retained source version 1:2024-08-01:current:c6888daf7bd0a6a4ca340a3b96cdef9be4eb8fc53e4115190aac78882035bdae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32843370/) (`pubmed-observation-pmid-32843370-2024-08-01-c6888daf7bd0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-32843370-pasireotide-v1 SHA-256: c769c897c4ed4ef5cb14726837ce35efe45a463f7e16dfdf400f5e04ac839d78.

---

<a id="pubmed-pmid-35518928-pasireotide-v1"></a>

## Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.

> PubMed lists PMID 35518928 in Frontiers in endocrinology as Case Reports, Review, Journal Article, with publication-date metadata of 2022-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35518928-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-11-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35518928-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-35518928-pasireotide-v1
- Content SHA-256: `2cd5f05495eb7cfc3f6915376a896b61d30345c4d128d3f10f103759152d1a40`

### Claims and source pins

#### Headline

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature. ([`pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8`](#source-pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8))

#### Summary

PubMed lists PMID 35518928 in Frontiers in endocrinology as Case Reports, Review, Journal Article, with publication-date metadata of 2022-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8`](#source-pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8))

#### Paragraph 1

PubMed lists PMID 35518928 in Frontiers in endocrinology as Case Reports, Review, Journal Article, with publication-date metadata of 2022-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8`](#source-pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8`](#source-pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8))

### Sources

<a id="source-pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8"></a>
- **Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature. · retained source version 1:2023-11-05:current:9a90af70e9e8bfbfc5452e2694cb0b0583da5017669a171872df67e562ec83ad** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35518928/) (`pubmed-observation-pmid-35518928-2023-11-05-9a90af70e9e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-35518928-pasireotide-v1 SHA-256: 2cd5f05495eb7cfc3f6915376a896b61d30345c4d128d3f10f103759152d1a40.

---

<a id="pubmed-pmid-35670988-pasireotide-v1"></a>

## Pituitary acting drugs: cabergoline and pasireotide.

> PubMed lists PMID 35670988 in Pituitary as Journal Article, Review, with publication-date metadata of 2022-06-07 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35670988-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35670988-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-35670988-pasireotide-v1
- Content SHA-256: `eb7e0ae7222b330b1b97103f55182aff1303cde61340a59c1ce86a00203e0a13`

### Claims and source pins

#### Headline

Pituitary acting drugs: cabergoline and pasireotide. ([`pubmed-observation-pmid-35670988-2026-10-30-736d5b468313`](#source-pubmed-observation-pmid-35670988-2026-10-30-736d5b468313))

#### Summary

PubMed lists PMID 35670988 in Pituitary as Journal Article, Review, with publication-date metadata of 2022-06-07 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35670988-2026-10-30-736d5b468313`](#source-pubmed-observation-pmid-35670988-2026-10-30-736d5b468313))

#### Paragraph 1

PubMed lists PMID 35670988 in Pituitary as Journal Article, Review, with publication-date metadata of 2022-06-07 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35670988-2026-10-30-736d5b468313`](#source-pubmed-observation-pmid-35670988-2026-10-30-736d5b468313))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35670988-2026-10-30-736d5b468313`](#source-pubmed-observation-pmid-35670988-2026-10-30-736d5b468313))

### Sources

<a id="source-pubmed-observation-pmid-35670988-2026-10-30-736d5b468313"></a>
- **Pituitary acting drugs: cabergoline and pasireotide. · retained source version 1:2026-10-30:current:736d5b46831312cff35752a3c1b4748cc951a8230e26bd60496eac66a5ace105** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35670988/) (`pubmed-observation-pmid-35670988-2026-10-30-736d5b468313`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pituitary acting drugs: cabergoline and pasireotide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-35670988-pasireotide-v1 SHA-256: eb7e0ae7222b330b1b97103f55182aff1303cde61340a59c1ce86a00203e0a13.

---

<a id="pubmed-pmid-35931640-pasireotide-v1"></a>

## Second line treatment of acromegaly: Pasireotide or Pegvisomant?

> PubMed lists PMID 35931640 in Best practice & research. Clinical endocrinology & metabolism as Meta-Analysis, Journal Article, Review, with publication-date metadata of 2022-07-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35931640-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-12-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35931640-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-35931640-pasireotide-v1
- Content SHA-256: `6893ecc5577b3c470353a2cb389f1f5011714d72966825f5909517bfbe3b1821`

### Claims and source pins

#### Headline

Second line treatment of acromegaly: Pasireotide or Pegvisomant? ([`pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a`](#source-pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a))

#### Summary

PubMed lists PMID 35931640 in Best practice & research. Clinical endocrinology & metabolism as Meta-Analysis, Journal Article, Review, with publication-date metadata of 2022-07-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a`](#source-pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a))

#### Paragraph 1

PubMed lists PMID 35931640 in Best practice & research. Clinical endocrinology & metabolism as Meta-Analysis, Journal Article, Review, with publication-date metadata of 2022-07-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a`](#source-pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a`](#source-pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a))

### Sources

<a id="source-pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a"></a>
- **Second line treatment of acromegaly: Pasireotide or Pegvisomant? · retained source version 1:2022-12-22:current:da181b76d59a089c0d9a3dfd2087412afec7954fe4720cc2dbfd26f046582a7b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35931640/) (`pubmed-observation-pmid-35931640-2022-12-22-da181b76d59a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Second line treatment of acromegaly: Pasireotide or Pegvisomant?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-35931640-pasireotide-v1 SHA-256: 6893ecc5577b3c470353a2cb389f1f5011714d72966825f5909517bfbe3b1821.

---

<a id="pubmed-pmid-38577574-pasireotide-v1"></a>

## Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.

> PubMed lists PMID 38577574 in Frontiers in endocrinology as Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-03-21 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38577574-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38577574-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38577574-pasireotide-v1
- Content SHA-256: `ea676f129326c38ba95400af3e9db8916db04d3c4287dfbd0e64fd6a016a1624`

### Claims and source pins

#### Headline

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study. ([`pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8`](#source-pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8))

#### Summary

PubMed lists PMID 38577574 in Frontiers in endocrinology as Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-03-21 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8`](#source-pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8))

#### Paragraph 1

PubMed lists PMID 38577574 in Frontiers in endocrinology as Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-03-21 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8`](#source-pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8`](#source-pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8))

### Sources

<a id="source-pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8"></a>
- **Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study. · retained source version 1:2026-06-03:current:ecf185f4e6b8f6edd4b12dc0a9c8680ea6288f5baa7a162bae9cdc517de5e9e8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38577574/) (`pubmed-observation-pmid-38577574-2026-06-03-ecf185f4e6b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38577574-pasireotide-v1 SHA-256: ea676f129326c38ba95400af3e9db8916db04d3c4287dfbd0e64fd6a016a1624.

---

<a id="pubmed-pmid-38713182-pasireotide-v1"></a>

## Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.

> PubMed lists PMID 38713182 in Endocrine-related cancer as Journal Article, Multicenter Study, with publication-date metadata of 2024-05-27 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38713182-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38713182-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38713182-pasireotide-v1
- Content SHA-256: `052f0c9593ca6c6dc78770b9e387b2230feab59649b6da5ec41f0dd0847eeacc`

### Claims and source pins

#### Headline

Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. ([`pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34`](#source-pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34))

#### Summary

PubMed lists PMID 38713182 in Endocrine-related cancer as Journal Article, Multicenter Study, with publication-date metadata of 2024-05-27 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34`](#source-pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34))

#### Paragraph 1

PubMed lists PMID 38713182 in Endocrine-related cancer as Journal Article, Multicenter Study, with publication-date metadata of 2024-05-27 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34`](#source-pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34`](#source-pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34))

### Sources

<a id="source-pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34"></a>
- **Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. · retained source version 1:2026-09-16:current:d6d4471b5d34e3f4eafe6fce2b2da796ab83f8a51f6bd6736cca61756914386b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38713182/) (`pubmed-observation-pmid-38713182-2026-09-16-d6d4471b5d34`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38713182-pasireotide-v1 SHA-256: 052f0c9593ca6c6dc78770b9e387b2230feab59649b6da5ec41f0dd0847eeacc.

---

<a id="pubmed-pmid-38817802-pasireotide-v1"></a>

## Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences.

> PubMed lists PMID 38817802 in Drugs in context as Journal Article, with publication-date metadata of 2024-05-20 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38817802-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-06-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38817802-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38817802-pasireotide-v1
- Content SHA-256: `e1f2109c7cf09333e13604b648aeea20101bf3c653ea1073b3af383599a82a20`

### Claims and source pins

#### Headline

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences. ([`pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5`](#source-pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5))

#### Summary

PubMed lists PMID 38817802 in Drugs in context as Journal Article, with publication-date metadata of 2024-05-20 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5`](#source-pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5))

#### Paragraph 1

PubMed lists PMID 38817802 in Drugs in context as Journal Article, with publication-date metadata of 2024-05-20 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5`](#source-pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5`](#source-pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5))

### Sources

<a id="source-pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5"></a>
- **Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences. · retained source version 1:2024-06-01:current:fa30890b18a5294dee26ce407209bb756c08fb74560057f5b7df4e3ae8aa4706** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38817802/) (`pubmed-observation-pmid-38817802-2024-06-01-fa30890b18a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38817802-pasireotide-v1 SHA-256: e1f2109c7cf09333e13604b648aeea20101bf3c653ea1073b3af383599a82a20.

---

<a id="pubmed-pmid-38982703-pasireotide-v1"></a>

## The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LAR.

> PubMed lists PMID 38982703 in Endocrine, metabolic & immune disorders drug targets as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38982703-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-07-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38982703-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38982703-pasireotide-v1
- Content SHA-256: `10b166aee658551be79f13b33dace9f269ea7a02861a818f10730ca4504a22b1`

### Claims and source pins

#### Headline

The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LAR. ([`pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22`](#source-pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22))

#### Summary

PubMed lists PMID 38982703 in Endocrine, metabolic & immune disorders drug targets as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22`](#source-pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22))

#### Paragraph 1

PubMed lists PMID 38982703 in Endocrine, metabolic & immune disorders drug targets as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22`](#source-pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22`](#source-pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22))

### Sources

<a id="source-pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22"></a>
- **The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LAR. · retained source version 1:2024-07-10:current:acd0e77b9a2230f664868a9b81e4622825abdff17342faa482bb71f9d8f19f48** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38982703/) (`pubmed-observation-pmid-38982703-2024-07-10-acd0e77b9a22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LAR." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-38982703-pasireotide-v1 SHA-256: 10b166aee658551be79f13b33dace9f269ea7a02861a818f10730ca4504a22b1.

---

<a id="pubmed-pmid-39072348-pasireotide-v1"></a>

## Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.

> PubMed lists PMID 39072348 in Diabetes, metabolic syndrome and obesity : targets and therapy as Journal Article, Review, with publication-date metadata of 2024-07-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39072348-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-07-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39072348-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-39072348-pasireotide-v1
- Content SHA-256: `f13c35823cc404a1bf9ad5586bcff517bd06e74d87b9057dc4bf4a8830d1fac3`

### Claims and source pins

#### Headline

Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review. ([`pubmed-observation-pmid-39072348-2024-07-30-050569a67f68`](#source-pubmed-observation-pmid-39072348-2024-07-30-050569a67f68))

#### Summary

PubMed lists PMID 39072348 in Diabetes, metabolic syndrome and obesity : targets and therapy as Journal Article, Review, with publication-date metadata of 2024-07-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39072348-2024-07-30-050569a67f68`](#source-pubmed-observation-pmid-39072348-2024-07-30-050569a67f68))

#### Paragraph 1

PubMed lists PMID 39072348 in Diabetes, metabolic syndrome and obesity : targets and therapy as Journal Article, Review, with publication-date metadata of 2024-07-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39072348-2024-07-30-050569a67f68`](#source-pubmed-observation-pmid-39072348-2024-07-30-050569a67f68))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39072348-2024-07-30-050569a67f68`](#source-pubmed-observation-pmid-39072348-2024-07-30-050569a67f68))

### Sources

<a id="source-pubmed-observation-pmid-39072348-2024-07-30-050569a67f68"></a>
- **Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review. · retained source version 1:2024-07-30:current:050569a67f687f4a9b29e9f8ce23626f2a77f7a250cf60e26848274c28dc5f49** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39072348/) (`pubmed-observation-pmid-39072348-2024-07-30-050569a67f68`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-39072348-pasireotide-v1 SHA-256: f13c35823cc404a1bf9ad5586bcff517bd06e74d87b9057dc4bf4a8830d1fac3.

---

<a id="pubmed-pmid-39129819-pasireotide-v1"></a>

## Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly.

> PubMed lists PMID 39129819 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2024-08-09 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39129819-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-08-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39129819-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-39129819-pasireotide-v1
- Content SHA-256: `1f94967001a336a54717a158355abedecfe94210c18cb6ce033c08096aac9b23`

### Claims and source pins

#### Headline

Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. ([`pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3`](#source-pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3))

#### Summary

PubMed lists PMID 39129819 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2024-08-09 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3`](#source-pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3))

#### Paragraph 1

PubMed lists PMID 39129819 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2024-08-09 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3`](#source-pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3`](#source-pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3))

### Sources

<a id="source-pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3"></a>
- **Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. · retained source version 1:2024-08-15:current:e2bacc5903e34709c3c5c3a00c7227d4a7d789bd9a56f3ff0fa8c9d9f3538acf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39129819/) (`pubmed-observation-pmid-39129819-2024-08-15-e2bacc5903e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-39129819-pasireotide-v1 SHA-256: 1f94967001a336a54717a158355abedecfe94210c18cb6ce033c08096aac9b23.

---

<a id="pubmed-pmid-40283624-pasireotide-v1"></a>

## Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study.

> PubMed lists PMID 40283624 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-04-18 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40283624-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-04-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40283624-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-40283624-pasireotide-v1
- Content SHA-256: `9595d730561c96b06eda66f9b73bdaff765cd3219b34074a3281a8fd15cca27b`

### Claims and source pins

#### Headline

Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study. ([`pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa`](#source-pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa))

#### Summary

PubMed lists PMID 40283624 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-04-18 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa`](#source-pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa))

#### Paragraph 1

PubMed lists PMID 40283624 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-04-18 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa`](#source-pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa`](#source-pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa))

### Sources

<a id="source-pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa"></a>
- **Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study. · retained source version 1:2025-04-28:current:6d772ff715faa1a774dfc7f8465cc7c14643e622a074c7fbf9b72ef64c6ec2f9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40283624/) (`pubmed-observation-pmid-40283624-2025-04-28-6d772ff715fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-40283624-pasireotide-v1 SHA-256: 9595d730561c96b06eda66f9b73bdaff765cd3219b34074a3281a8fd15cca27b.

---

<a id="pubmed-pmid-41323967-pasireotide-v1"></a>

## Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.

> PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41323967-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41323967-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-41323967-pasireotide-v1
- Content SHA-256: `63e12253f53080efe1d4b6318dc1ebffeed257bdb786d0f95490fcaf21f8affc`

### Claims and source pins

#### Headline

Real-life data on pasireotide in monotherapy or combined in active Cushing's disease. ([`pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96`](#source-pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96))

#### Summary

PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96`](#source-pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96))

#### Paragraph 1

PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96`](#source-pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96`](#source-pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96))

### Sources

<a id="source-pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96"></a>
- **Real-life data on pasireotide in monotherapy or combined in active Cushing's disease. · retained source version 1:2025-12-03:current:129259ecbb96e734d111b16639cb16108a357fc19e0a65caa21f1bf942778009** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41323967/) (`pubmed-observation-pmid-41323967-2025-12-03-129259ecbb96`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-life data on pasireotide in monotherapy or combined in active Cushing's disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-41323967-pasireotide-v1 SHA-256: 63e12253f53080efe1d4b6318dc1ebffeed257bdb786d0f95490fcaf21f8affc.

---

<a id="pubmed-pmid-42778805-pasireotide-v1"></a>

## Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.

> PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42778805-pasireotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42778805-pasireotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-42778805-pasireotide-v1
- Content SHA-256: `1dbe12581f156e6c11d16ff2b4aca6520fd27a8dcff467b34549626df259196f`

### Claims and source pins

#### Headline

Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas. ([`pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f`](#source-pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f))

#### Summary

PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f`](#source-pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f))

#### Paragraph 1

PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f`](#source-pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f`](#source-pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f))

### Sources

<a id="source-pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f"></a>
- **Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas. · retained source version 1:2026-10-31:current:0ea9a68b7b8ff277d2b491dd26927c975a97729c2ea2323b3f81cb955a6a7eae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42778805/) (`pubmed-observation-pmid-42778805-2026-10-31-0ea9a68b7b8f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/pasireotide.json#pubmed-pmid-42778805-pasireotide-v1 SHA-256: 1dbe12581f156e6c11d16ff2b4aca6520fd27a8dcff467b34549626df259196f.

